Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Ovarian Steroid Cell Tumors: An Immunohistochemical Study Including a Comparison of Calretinin with Inhibin

Deavers, Michael T. M.D.; Malpica, Anais M.D.; Ordonez, Nelson G. M.D.; Silva, Elvio G. M.D.

International Journal of Gynecological Pathology: April 2003 - Volume 22 - Issue 2 - p 162-167
ORIGINAL CONTRIBUTIONS
Buy

Ovarian steroid cell tumors, not otherwise specified (SCTs, NOS) are uncommon sex cord-stromal tumors that may be difficult to distinguish from other oxyphilic or clear-cell neoplasms. Immunohistochemical staining for inhibin, although generally useful in the diagnosis of SCTs, NOS, is not positive in every case and not all laboratories have this marker available. Recently, it has been reported that calretinin is expressed by sex cord-stromal tumors. We studied six SCTs, NOS for both calretinin and inhibin expression to evaluate the sensitivity of calretinin in comparison to inhibin. We also tested for CD99, Melan-A (A103), and S-100, other markers reported to be positive in these tumors. HMB-45 and MART-1 (Ab3) completed our panel of markers. All six tumors were positive for both calretinin and inhibin. Calretinin positivity was present in 60% to >90% of tumor cells, whereas inhibin reactivity ranged from <5% to >90% of tumor cells. Membranous staining for CD99 was present in one tumor. S-100-positive cells were seen in two tumors, whereas four tumors were immunoreactive for HMB-45. All six tumors were positive for Melan-A (A103), but in general the staining was less diffuse than with calretinin. All of the tumors were essentially negative for MART-1 (Ab3). The consistent diffuse staining of the tumors in this study for calretinin, in comparison to inhibin and Melan-A (A103), suggests that it is a sensitive marker for SCTs, NOS. MART-1 (Ab3) immunostaining may be useful for cases in which melanoma is considered in the differential diagnosis.

From the Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

Presented in part at the Annual Meeting of the United States and Canadian Academy of Pathology, March, 2001.

Address correspondence and reprint requests to Michael T. Deavers, M.D., Department of Pathology, Box 85, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.

©2003International Society of Gynecological Pathologists